Nirsevimab resistance in respiratory syncytial virus-B: virological signal without meaningful clinical impact.

Mésinèle J, Prevost B, Nathan N, Guillot L, Corvol H

Open source

DOI
10.1016/j.lanmic.2026.101529
Published
2026 Sep 16
Container
The Lancet. Microbe
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.lanmic.2026.101529,
  title = {Nirsevimab resistance in respiratory syncytial virus-B: virological signal without meaningful clinical impact.},
  author = {Mésinèle J and Prevost B and Nathan N and Guillot L and Corvol H},
  year = {2026},
  journal = {The Lancet. Microbe},
  doi = {10.1016/j.lanmic.2026.101529},
  url = {https://doi.org/10.1016/j.lanmic.2026.101529}
}

RIS

TY  - JOUR
TI  - Nirsevimab resistance in respiratory syncytial virus-B: virological signal without meaningful clinical impact.
AU  - Mésinèle J
AU  - Prevost B
AU  - Nathan N
AU  - Guillot L
AU  - Corvol H
PY  - 2026
JO  - The Lancet. Microbe
DO  - 10.1016/j.lanmic.2026.101529
UR  - https://doi.org/10.1016/j.lanmic.2026.101529
ER  - 

APA

J, M., B, P., N, N., L, G., & H, C. (2026). Nirsevimab resistance in respiratory syncytial virus-B: virological signal without meaningful clinical impact.. The Lancet. Microbe. https://doi.org/10.1016/j.lanmic.2026.101529

Source records